Why Halozyme Therapeutics Is Soaring in After-Hours Trading Today

NEW YORK (TheStreet) -- Halozyme Therapeutics  (HALO) surged in after-hours trading after the biopharmaceutical company announced it would resume its PEGPH20 clinical trial.

Halozyme said the FDA lifted the clinical hold on patient enrollment and dosing of PEGPH20 in its ongoing Phase 2 trial evaluating the treatment in patients with stage IV metastatic pancreatic cancer. The FDA has allowed the study to resume under an amended protocol, and Halozyme expects patient enrollment to restart after Independent Review Boards review and approve the change protocol.

"We are committed to the development of PEGPH20 in pancreatic cancer. Halozyme worked diligently with the FDA and the DMC to develop the plan to allow the study to restart," said President and CEO Dr. Helen Torley in a company statement. "We are pleased to be able to continue enrolling patients in this clinical program as there remains a significant need for new treatment options for pancreatic cancer patients."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 12% to $9.05 at 4:26 p.m.

HALO Price Chart

HALO Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Good Stocks Are There for the Picking

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme